Indonesia

Health product regulation in Indonesia is primarily governed by BPOM (Badan Pengawas Obat dan Makanan), established under Government Regulation No. 80 of 2017 and further empowered by Law No. 11 of 2020 on Job Creation (Omnibus Law). BPOM oversees the registration, surveillance, and market authorization of pharmaceuticals, medical devices, in vitro diagnostics, and related health products. Medical devices and diagnostics fall under a separate but coordinated framework administered by the Ministry of Health (Kementerian Kesehatan, Kemenkes) through its Directorate General of Pharmaceutical and Medical Devices (Direktorat Jenderal Kefarmasian dan Alat Kesehatan), while pharmaceuticals and biologics are handled directly by BPOM. All health products must obtain official market authorization (izin edar) before commercial distribution, and the review process involves technical assessment, administrative verification, and in some cases laboratory testing or clinical data review.

Applicants are required to appoint a local Indonesian legal entity or authorized representative (importer/distributor) to submit registration dossiers on behalf of foreign manufacturers. Indonesia accepts dossiers aligned with ASEAN Common Technical Dossier (ACTD) and ASEAN Common Technical Requirements (ACTR) formats, and increasingly references ICH Common Technical Document (CTD) guidelines for pharmaceutical submissions. Class-based risk stratification applies to medical devices, with Class A (low risk) to Class D (high risk) determining the depth of technical review required. Recent reforms under the Omnibus Law and Presidential Regulation No. 32 of 2024 have introduced provisions for expedited pathways for priority health products, risk-based market authorization, and enhanced post-market surveillance obligations. Digital health products and Software as a Medical Device (SaMD) are subject to emerging regulatory guidance issued by Kemenkes, reflecting Indonesia's growing focus on health digitalization under the national Health Transformation agenda.

Public procurement of health products in Indonesia is centrally coordinated through the Ministry of Health (Kemenkes) and executed via the National Government Procurement Agency (Lembaga Kebijakan Pengadaan Barang/Jasa Pemerintah, LKPP). The national health insurance program, Jaminan Kesehatan Nasional (JKN), administered by BPJS Kesehatan, is the dominant driver of public sector demand and procurement. Pharmaceutical procurement for JKN facilities is largely channeled through e-Catalogue (e-Katalog), an electronic procurement platform maintained by LKPP, where manufacturers or their local partners must be listed to supply to government health facilities. Medical device and diagnostic procurement follows a similar e-Catalogue model, with formulary inclusion linked to the National Formulary (Formularium Nasional) for pharmaceuticals and the equivalent approved lists for devices. Regional governments (provincial and district levels) retain significant autonomy in procurement planning and budget allocation for primary healthcare infrastructure, creating a layered federal-regional dynamic that manufacturers must navigate.

The private sector represents a substantial and growing share of the Indonesian health market, served through independent distributors, hospital procurement committees, and retail pharmacy chains, with no centralized tendering mechanism at the private level. Indonesia participates in donor-funded health programs supported by organizations including the Global Fund (for HIV, tuberculosis, and malaria programs), Gavi (for immunization supply chains), UNICEF (for maternal and child health commodities), and USAID-funded initiatives, which introduce additional procurement channels with their own compliance and quality assurance requirements. A significant policy consideration is Indonesia's local content (Tingkat Komponen Dalam Negeri, TKDN) requirement, which mandates minimum local content thresholds for health products procured by government entities, incentivizing local manufacturing partnerships, technology transfer arrangements, and in-country production. Products meeting TKDN thresholds receive preferential scoring in government tenders, making local manufacturing or assembly partnerships strategically important for sustained market access in the public sector.